Aurora Cannabis Rejects $272 Million Curaleaf Acquisition

The proposal, valued at $4 per share, consists of 0.3463 Curaleaf voting shares plus 75 cents in cash, capped at a maximum of $5 per share. After consulting with independent financial and legal advisors, Aurora’s special committee labeled the bid opportunistic. Leadership specifically pointed to a structural imbalance in the offer, which would grant Aurora shareholders only 3.2% of voting power despite their 7.7% stake in the potential combined entity.

Instead of ceding control, Aurora is doubling down on its standalone trajectory. The board highlighted record international revenue and high profit margins as evidence that the company is better positioned on its own. Recent investments in EU-GMP compliant cultivation and manufacturing capacity serve as the cornerstone of this growth strategy, a path the company maintains will provide greater returns to investors than the current acquisition terms.